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Abstract. Dose-dependent effects of intravenously ad- 
ministered lorazepam on psychophysiological activity 
during rest and mental stress were studied in order to 
examine differential responses to doses which may induce 
anxiolysis or sedation. In a double-blind randomized 
cross-over study, nine male volunteers participated in a 
placebo and a lorazepam session, during which the sub- 
jects repeatedly performed a 10-min version of the 
Stroop Color Word Test (CWT), with t0 min of rest 
between the CWTs. Lorazepam was administered before 
each rest period in increasing doses of 0.0, 0.06, 0.13, 0.25 
and 0.5 mg (total cumulative dose: 0.94 mg). Heart rate 
showed a dose-dependent decrease during rest with an 
ED50 of 0.13mg lorazepam, while lorazepam had no 
effect on the cardiovascular nd plasma catecholamine 
response magnitudes tothe CWT. Subjective thtigue and 
reaction time increased significantly after 0.94 mg lor- 
azepam, while at the same dose vigor decreased; state 
anxiety after the CWT was not influenced by lorazepam. 
These data show differential effects of lorazepam on 
cardiovascular, biochemical nd psychological function. 
While heart rate was suppressed at low doses during rest 
and reaction time and subjective fatigue increased at 
doses which induced sedation, state anxiety and physio- 
logical response patterns to he CWT were not influenced 
by lorazepam. 
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Anxiety is an emotional state in which psychic distress is 
associated with widespread physiological and biochemi- 
cal changes, induced primarily by activation of the sym- 
pathetic adrenal-medullary s stem (Lader and Bruce 
1986). In order to study the specificity of the relation 
between sympathetic adrenal-medullary activity and 
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psychological function during anxiety or stress, con- 
trolled situations are needed in which anxiety or stress 
are induced experimentally. The usefulness of the Stroop 
Color Word Test (CWT) as a stress-inducing perfor- 
mance task has been shown previously (Frankenhaeuser 
and Johansson 1976; Hjemdahl et al. 1984; Tulen et al. 
1989). The CWT induces ympathetic adrenal-medullary 
activation as shown by increased cardiovascular ctivity 
and catecholamine s cretion, in addition to psychic dis- 
tress (Tulen et al. 1989). However, whether specific mech- 
anisms related to anxiety, a non-specific increase in 
arousal or activation of effort mechanisms necessary to 
cope with the task (Sanders 1983) are responsible for the 
observed reactions is not clear. In order to analyse the 
mechanisms responsible for the responses to the CWT, 
administration f anxiolytic drugs may prove to be help- 
ful. The benzodiazepines are the preferred anxiolytic 
drugs used today and induce different pharmacological 
effects at different dose levels: anxiolysis at low doses and 
sedation or sleep at higher doses (Geller and Seifter 
1960). Suppression of sympathetic nervous ystem activ- 
ity by benzodiazepines has been observed in man at doses 
which induce sedation (Duka et al. 1986; Roy-Byrne t 
al. 1988). These effects might, however, be different at 
doses which induce anxiolysis. It is therefore of interest 
to study specific dose-dependent sympathetic adrenal- 
medullary effects in relation to rest levels and stress- 
inducing performance t sts. 
In this study we investigated the cumulative dose- 
response ffects of intravenously administered lorazepam 
during rest and during presentation of the CWT in a 
placebo-controlled design in healthy male volunteers. 
Lorazepam was chosen because of its short distribution 
half-life (intravenous: :k4 rain; Greenblatt et al. 1977) 
which allowed us to create a cumulative dose-response 
curve with five different doses within one experimental 
session. In addition, lorazepam has no active metabolites 
(Kyriakopoulos et al. 1978) which could complicate the 
interpretation of data. Five doses were administered, 
resulting in a total cumulative dose of ca. 1 mg lor- 
azepam. The oral dose-equivalent of 1mg lorazepam IV 
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is circa 2 rag: a dose which has sedative effects (Patat  et 
al. 1987; Preston et al. 1989). By s tudy ing  the dose- 
dependency  o f  effects o f  lo razepam IV on  sympathet ic  
adrena l -medu l la ry  act ivity and  psychological  funct ion  
dur ing  rest and  CWT,  differential  responses related to 
anxiolysis and  sedat ion  dur ing  rest and  menta l  stress 
were explored, 
Materials and methods 
Subjects, design and procedure 
Nine male volunteers (mean: 23.9 years, range: 21-29) participated 
in a randomized double-blind cross-over study in two experimental 
sessions each: a placebo (PLA) and a lorazepam (LOR) session. The 
study was approved by the Medical Ethical Committee of the 
University Hospital DijkNgt. All subjects gave written informed 
consent and were paid for their participation i  the study. The 
subjects underwent a medical screening: all were in good physical 
condition. Six of the nine subjects were non-smokers, three subjects 
smoked moderately (< 5 cigarettes per day); heavy drinking was 
not reported. 
During both sessions the subjects performed on five consecutive 
occasions a 10-min version of the Stroop Color Word Test (CWT), 
with 10 rain of rest between the CWTs. Each CWT was followed 
by a Simple Reaction Time task (SRT) (duration of task: 5 min). 
A schematic time-bar of the experimental procedures during each 
session is shown in Fig. 1. During the PLA session, a PLA injection 
(2.5 ml saline, slowly injected over 1 rain) was administered five 
times intravenously, each time before the rest periods. During the 
LOR session, LOR was administered intravenously (in 2.5 ml saline 
solution, slowly injected over 1 rain) before each rest period in 
increasing doses of 0.0mg, 0.0625mg, 0.125mg, 0.25mg and 
0.5 mg (total cumulative dose: 0.9375 rag). Lorazepam has a distri- 
bution half-life (intravenous) of about 4 min; within 15 rain a distri- 
bution of > 95% is reached (Greenblatt e al. 1977) and its elimina- 
tion half-life is about 12-13 h (Kyriakopoulos et al. 1978; Boulen- 
get et al. 1984). The consecutive doses of LOR used in this study 
can therefore be supposed to induce a cumulative ffect. 
The two experimental sessions per subject were recorded on 
separate days, 1 week apart. The subjects were requested to abstain 
from coffee, tea and smoking on both day's, from the moment they 
got out of bed in the morning until they arrived in the laboratory. 
During the experimental sessions coffee, tea and smoking were not 
allowed. Before the start of each session, the subjects were requested 
to void urine and drink a glass of mineral water. Each session lasted 
from 09:00 to 12:30 hours: physiological, biochemical nd psycho- 
logical measurements were performed uring this period. The sub- 
jeers were sitting in a comfortable chair during the entire session. 
After the session, a standard light lunch was served. Because seda- 
tive effects are observed after an intravenous cumulative dose of 
1 mg LOR, in the afternoon the subjects remained in the hospital 
in a room where they could read or study. At 18:00 hours they were 
allowed to go home, after approval by the MD. 
Tests 
The Stroop Color Word Test (CWT)~ The CWT consists of four 
words (red, green, blue, yellow) which are presented on videotape, 
one word at a time, in four different colors (red, green, blue, yellow). 
The stimulus presentation a d the interstimulus interval last about 
1.5-2.0 s and conform to previously described versions of this test 
(Frankenhaeuser and Johansson 1976; Tulen et al. 1989). The 
subject has to indicate the color of the word on an answer sheet, 
with the specific request to do their very best and make as few errors 
as possible. The test induces acognitive conflict (Stroop 1935), while 
time-pressure effects are added due to the rapid presentation f the 
stimuli. Within each session, five different 10-min versions of the 
CWT were used to avoid learning effects concerning word sequence. 
The number of errors made during each CWT was counted; the 
percentage of errors per CWT was calculated relative to the total 
number of stimuli presented. In order to become familiar with the 
specific requirements of the task, a 2-min practice tape was pre- 
sented at the beginning of the first session for instruction purposes. 
Simple Reaction Time Task (SRT). A 5-min version of a visual 
reaction-time task was presented on a Personal Computer (Olivetti). 
The subject was requested to press a button as soon as possible after 
a small red square appeared on the monitor. The interstimulus- 
interval varied randomly between 1and 5 s in order to avoid stim- 
ulus anticipation effects. Reaction time was calculated with an 
accuracy of 1 ms. 
Recordings 
Psychological. Before and after the whole session and immediately 
after each CWT, changes in subjective mood were assessed by 
means of a shortened version of the vigor and fatigue subscales of 
the Profile Of Mood States (POMS) (McNair et al. 1971) which was 
validated for the Dutch population (Wald and Mellenbergh 1990) 
and a shortened state version of the State-Trait Anxiety Inventory 
(STAI) (van der Ploeg et al. 1980; Knippenberg et al. 1990). 
Physiological. A Nihon Kohden polygraph was used to amplify and 
calibrate the physiological signals. All signals were monitored con- 
tinuously on paper by means of a SiemensoElema EEG mingograf, 
and at the same time recorded analogue on a Racal instrumentation 
recorder. The ECG was derived using a precordial lead. Blood pres- 
sure was recorded using a servo-plethysmo-manometer for con- 
tinuous, non-invasive measurement of finger arterial blood pres- 
sure, employing the volume clamp technique of Pefi~z (Pefi~tz et al. 
1976; Wesseling et al. 1982; Settels and Wesseling 1985) (Finapres 
2300 NIBP monitor, Ohmeda systems). 
ECG and blood pressure recordings were digitized with a sample 
frequency of 102.4 Hz on a Personal Computer (Olivetti), connected 
to a Labmaster Analogue/Digital converter. Before A/D conversion 
a Schmitt rigger was used to trigger the incidence of the R-waves 
in the ECG; the output pulses of the trigger were fed into the 
converter for sampling. The time between the output pulses (inter- 
beat interval) was measured with a resolution of 10 ms. Systolic, 
diastolic and mean blood pressure (SBP, DBP, MBP) were defined 
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Fig. 1. Schematic time-bar of the experimental procedures during the PLA and the LOR session. Injection moment (]'); CWT (hatched): 
Color Word Test; POMS : Profile Of Mood States, STAI: State-Trait Anxiety Inventory (blank); SRT (cross-hatched): Simple Reaction 
Time task; PLA : placebo; LOR: lorazepam; R (--): rest period; blood sample (*) 
per R-R interval of the ECG with a resolution of 0.2 mmHg. 
Obtaining blood samples caused momentary increases in heart rate 
and blood pressure and induced some movement artifacts: these 
periods were excluded from the analyses. One blood pressure re- 
cording showed technical shortcomings and was not analysed. 
Mean heart rate (in BPM) and mean SBP, DBP and MBP were 
calculated per rest period and for the first 5 min of each CWT. Only 
heart rate and MBP data will be presented because SBP and DBP 
data showed the same effects as MBP. 
Biochemical. Forty-five minutes before the start of the recordings, 
a catheter (Venflon, 18G, Viggo AB, Helsingborg, Sweden) was 
inserted in an antecubital vein of the non-dominant forearm, 
through which blood samples were drawn and infusion of LOR/ 
PLA took place. Blood samples (8 ml per sample) were drawn at the 
end of each rest period and during the second half of each CWT (the 
last 5 min) and collected in heparinized tubes containing 12 mg 
gtuthathione for assay of cat echolamines. The tubes were im- 
mediately placed on ice and centrifuged within 15 min. Plasma was 
subsequently frozen at - 70 ° C. The catecholamines were assayed 
by means of high-performance liquid chromatography with fluori- 
metric detection (Van der Hoorn et al. 1989). The limits of detection 
for adrenaline and noradrenaline were 0.3 pg, with a tow coefficient 
of variation (3-7%). 
Statistical analyses 
All analyses are presented for N = 9 with the exception of the blood 
pressure analyses (N = 8). For the physiological nd biochemical 
data, two-tailed Student's t-tests were used for pairwise com- 
parisons of the first rest periods of the two sessions to establish 
similarity of baseline values. Effects of LOR or PLA on rest values 
and CWT response magnitudes were analysed separately. CWT 
response magnitude was defined as the difference in heart rate, 
blood pressure or catecholamines during the CWT and the preced- 
ing rest period. One-factor analyses of variance for repeated mea- 
surements were performed within each condition (LOR or PLA), 
to analyse specific dose effects (LOR condition: factor Dose) or 
learning/habituation effects (PLA condition: factor Time). In order 
to assess the effect of the cumulative doses of LOR the factor of 
increase in doses was taken into account o contrast between the 
successive rest periods or CWT responses (factor for contrast be- 
tween the five dosages: 0, 1, 2, 4, 8). 
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Dose-related changes in subjective fatigue, vigor or anxiety were 
analysed per condition (LOR or PLA) with a nonparametric one- 
factor analysis of variance (Friedman) (Siegel 1956), while Wil- 
coxon tests (Siegel 1956) were applied for pairwise comparisons 
between the different dose levels within each condition. 
Where appropriate, dose-response curves were constructed and 
presented graphically, using the mean response of all individuals for 
each dose. EDsos were calculated for each individual per variable, 
using linear interpolation. Paired Student's t-tests were used to 
compare EDs0s of the different responses. 
Results 
Cardiovascular activity and plasma catecholamines 
Table 1 and Figs. 2 and 3 present he dose-related effects 
of  lo razepam on card iovascular  act ivity and p lasma 
catecholamines dur ing rest and CWT,  in relat ion to the 
placebo administrat ions.  
Rest periods. Baseline values o f  the PLA  and LOR ses- 
sions were similar for heart  rate ( t=-  1.61; P=0.15) ,  
MBP (t = 0.69; P = 0.51); p lasma adrenal ine (t = - 1.25; 
P=0.24)  and p lasma noradrenal ine ( t= -2 .11 ;  
P= 0.07). 
The analyses of  var iance indicated a significant Dose 
effect for heart  rate in the LOR session (Table 2). Af ter  
a cumulat ive dose of  0.19 mg LOR (LOR3)  heart  rate 
dur ing rest decreased signif icantly in compar ison  with 
the first rest per iod (R1) ( t=4.95;  P=0.001)  (Fig. 2). 
This effect appears  to be a specific effect of  LOR,  since 
no Time effect was observed in the PLA  session (Table 2). 
Wi th  regard to MBP,  a signif icant T ime effect was 
observed in the PLA  session (Table 2), indicat ing an 
increase in MBP in time. Increased values were observed 
mainly in the last two rest per iods (R5 and R6, Fig. 2), 
the difference between R1 and R5 being significant 
Table 1. Mean (SD) values of the cardiovascular data and the 
plasma catecholamine l vels during the consecutive rest periods 
(R I-R6) and the CWT response magnitudes (CWT 1-CWT5) of the 
LOR and PLA session. HRT: heart rate, MBP: mean blood pres- 
sure, ADR: adrenaline, NOR: noradrenaline 
R1 R2 R3 R4 R5 R6 CWT1 CWT2 CWT3 CWT4 CWT5 
HRT (bpm) PLA 64.1 65.4 63.9 64.0 61.8 61.7 8.6 6.5 6.3 5.9 5.3 
(7.3) (7.4) (9.1) (7.9) (9.8) (8.4) (4.9) (6.7) (7.4) (5.2) (6.2) 
LOR 70.4 68.7 64.7 64.0 63.6 64.6 8.6 4.5 6.2 7.4 7.7 
(9.8) (8.0) (7.8) (6.6) (7.5) (9.0) (8.5) (4.1) (3.7) (5.6) (7.3) 
MBP (mmHg) PLA 76.6 79.3 81.1 83.2 88.8 87.6 14.5 8.4 8.3 4.6 4.3 
(13.9) (13.8) (12.4) (12.5) (14.6) (i4.1) (5.6) (3.9) (5.8) (3.8) (9.1) 
LOR 79.7 82.3 84.7 85.5 88.3 88.9 17.7 9.2 7.9 8.2 8.0 
(15.3) (12.5) (13.6) (10.8) (11.2) (11.3) (11.1) (6.7) (4.2) (6.9) (4.5) 
ADR (pg/ml) PLA 41.3 37.0 33.0 30.1 33.1 38.3 18.3 16.8 20.0 23.8 13.8 
(25.5) (17.3) (16.1) (16.0) (18.I) (24.5) (19.2) (27.7) (19.2) (12.0) (12.4) 
LOR 31.4 30.1 27.8 29.2 29,8 30.8 22.6 19.8 20.2 15.6 15.3 
(18.7) (11.5) (10.9) (11.0) (10.2) (14.3) (t4.5) (12.8) (9.7) (8.4) (12.6) 
NOR (pg/ml) PLA 228.7 229.9 240.1 258.9 299.0 278.0 17.4 24.8 13.2 -3.0 - 19.3 
(69.8) (71.1) (77.7) (93.9) (110.8) (84.8) (40.0) (27.4) (36.3) (31.1) (50.6) 
LOR 196.6 200.7 206.7 225.2 214.7 230.1 15.1 28.7 9.7 -7.3 -6.8 
(52.2) (58.0) (71.6) (97.9) (66.7) (94.7) (30.0) (75.6) (18.6) (30.3) (35.8) 
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Fig, 2, Dose-related effects of lorazepam IV (© . . . . .  o) on car- 
diovascular activity during rest and CWT, in comparison with 
cardiovascular ctivity during placebo (e - -  e) administra- 
tions. The upper curve presents mean (and SEM) heart rate of the 
consecutive rest and CWT periods, calculated relative to R10.e. 
baseline: first rest period). The lower curve presents mean MBP, 
relative to R1 (see also Fig. 1) 
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Fig, 3. Dose-related effects of lorazepam IV on plasma catechol- 
amines during rest and CWT, in comparison with plasma catechol- 
amines during placebo administrations. ( ee legend to Fig. 2 for 
explanation). ADR = adrenaline. NOR = noradrenaline 
Table 2. Analyses of variance for repeated 
measures on the cardiovascular nd bio- 
chemical data: F-values and level of signi- 
ficance (P) of the within-subject effects 
of the main factor DOSE (injection 1-5) 
during the lorazepam session and the main HRT F 
factor Time during the placebo session are p< 
presented, Level of significance and 
F-values of the between-subjects effects are MBP F 
P_< also indicated. The analyses were p r- 
formed on the rest periods and the CWT ADR F 
response magnitudes separately. HRT: P_< 
heart rate; MBP: mean blood pressure; NOR F 
ADR: adrenaline; NOR : noradrenaline p < 
Rest periods CWT response magnitude 
Lorazepam Placebo Lorazepam Placebo 
Dose Subject Time Subject Dose Subject Time Subject 
7.62 716.78 0.54 773.69 1.11 19.76 1.13 t3.77 
0.001 0,001 0.710 0 .001 0,370 0.002 0.358 0.006 
2.28 424.21 17.78 308.55 6.00 26.62 6+36 27.61 
0.085 0.001 0.001 0.001 0.001 0.001 0.001 0.001 
0.33 62.55 2.23 36.93 0.9I 35.74 0.50 19.t5 
0.855 0.001 0.088 0 .001 0 .474  0.001 0.737 0.002 
1.08 93.88 4.93 92.30 0.88 4.73 2.39 0.74 
0.382 0.001 0.003 0 .001  0.490 0.066 0.074 0.418 
(t = -7 .22 ;  P<0.001) .  This increasing trend was not  
present in the LOR session. 
LOR had no effect on the plasma adrenal ine levels; 
trends during the PLA session were not observed (Ta- 
ble 2). 
Figure 3 indicates a gradual increase in plasma nor- 
adrenal ine l vels during rest in the PLA session (especial- 
ly during R5), which was not  present in the LOR session. 
The Time effect for plasma noradrenal ine t vels during 
the PLA session was significant (Table 2). 
CWT responses. The response magnitudes to CWT1 of 
the LOR and PLA session were similar for heart rate 
(t = - 0,02; P = 0.98), MBP (t = - 0.76; P = 0.47), plasma 
adrenal ine (t= 0.81 ; P= 0.45) and plasma noradrenal ine 
(t = -0 .06 ;  P=0,95) .  
There were no differences in heart rate responses to 
the consecutive CWTs in the PLA-session (factor Time: 
ns, Table 2), nor did LOR affect he response to the CWT 
(factor Dose: ns, Table 2). 
A decrease in response magnitude was observed for 
MBP, both in the PLA session (a significant Time effect, 
Table 2) and in the LOR session (a significant Dose 
effect, Table 2), indicating learning or habituation effects 
to the CWT within each condition, but no drug-specific 
effects (Fig. 2). 
LOR had no effect on the plasma catecholamine r - 
sponse magnitudes to the CWTs (Table 2). Figure 3 
shows an increase in plasma noradrenaline secretion 
during CWT1, CWT2 and CWT3 in relation to the 
preceding rest periods. However, thereafter a negative 
noradrenaline r sponse is observed uring CWT4 and 
CWT5. 
In summary, during the rest periods the only effect of 
LOR was a dose-dependent decrease in heart rate; car- 
diovascular and plasma catecholamine r sponse mag- 
nitudes to the CWT were not influenced by LOR. Nearly 
all variables howed significant (between) subject effects, 
indicating large interindividual variability (Tables 1 
and 2). 
Performance on tasks and subjective mood 
SRT. In Fig. 4 the dose-dependent effects of LOR on 
reaction time to the five consecutive SRTs are presented. 
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Fig. 4. Dose-related effects of lorazepam (O . . . . .  ©) on simple 
reaction time, in comparison with simple reaction time to placebo 
(o o) administrations. Mean (and SEM) reaction time in ms 
as measured uring the five consecutive SRTs of the LOR and PLA 
session 
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Reaction time to SRT1 of the LOR and PLA session was 
similar (t = 0.95; P = 0.37). A gradual increase in reaction 
time was observed in the LOR session (factor Dose: 
F=4.99, P=0.003; Subject: F= 392.64, P<0.001), but 
not in the PLA session (factor Time: F= 0.49, P=0.74; 
Subject: F= 408.38, P < 0.001), which indicates a specific 
drug effect. Reaction time was significantly increased 
after a cumulative dose of 0.94 mg LOR (SRT1-LOR 
versus SRT5-LOR: t=2.58; P=0.03; SRT5-LOR ver- 
sus SRT5-PLA: t=4.60; P=0.001) (Fig. 4). 
CWT performance. The percentage of errors to the 
CWTs of the PLA session decreased from 6.7% during 
CWT1 to 4.8% during CWT5 (non-significant dif- 
ference). During the LOR session the percentage of er- 
rors was similar f om CWT1 (6.6%) to CWT4 (5.2%), but 
increased significantly during CWT5 (17.1% ; t = - 5.02, 
P= 0.001) in comparison with CWT1. 
Subjective mood. Table 3 indicates the changes in fatigue, 
vigor and anxiety, as assessed immediately after each 
CWT, during the LOR and the PLA sessions. During the 
LOR session, we observed a gradual increase in fatigue: 
after a cumulative dose of 0.94 mg LOR (LOR5), this 
increase was significant in comparison with the baseline- 
values (z = -2.20; P= 0.02). Similarly, a significant de- 
crease in vigor was observed after a cumulative dose of 
0.94 mg LOR (LOR5) in comparison with baseline val- 
ues (z=-2.49;  P=0.01). Within-session analyses rev- 
ealed a significant Dose effect during the LOR session for 
both fatigue and vigor, but no effect at all on state 
anxiety. 
Dose~response curves 
Figure 5 shows the dose-response curves for heart rate, 
SRT, fatigue and vigor. The EDsos calculated on the 
basis of the individual dose-response curves were 
0.13 rag4- 0.06 (mean :t: SD, N= 9) for heart rate, 
0.324-0.23 (N= 8) for SRT, 0.244-0.27 (N= 7) for vigor 
and 0.47 4- 0.17 (N = 7) for fatigue. Two individuals did 
not show a response on the vigor and fatigue scales and 
therefore were excluded from the analysis. Paired 
Student's t-tests revealed asignificant difference between 
the EDsos for heart rate versus fatigue ( t=-  5.27, 
P=0.002, N= 7). From Fig. 5 it is apparent that the 
heart rate response has indeed reached a maximum, but 
this is not the case for the other three variables. 
Table 3. Mean and range values of subjec- 
tive mood (fatigue, vigor, anxiety) for the 
five consecutive assessments after each 
CWT during the PLA and the LOR ses- 
sion. Friedman analysis of variance were 
performed for the PLA and LOR session 
separately; Chi-square and level of signifi- 
cance (P-values) are indicated per session 
Fatigue 
PLA LOR 
session session 
1 7.2 (3) 7.2 (4) 
2 7.0 (2) 7.1 (3) 
3 7.2 (3) 7.8 (7) 
4 6.9 (3) 8.6 (8) 
5 7.9 (8) 10.2 (13) 
Chi 2 0.7 12.2 
P_< 0.95 0.01 
Vigor State anxiety 
PLA LOR PLA LOR 
session session session session 
t7.6 (11) 18.2 (15) 13.0 (6) 12.7 (5) 
17.9 (11) 17.1 (10) 12.8 (3) 13.0 (4) 
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Fig. 5. Mean (N= 9) cumulative dose-response curves of LOR on 
heart rate (e o) during rest, fatigue (A A), vigor 
(e . . . . .  e) and reaction time (SRT) (o o). Y-axis: heart 
rate (HRT) and vigor: % reduction; SRT and fatigue: % increase 
Therefore, the EDs0s ['or SRT, fatigue and vigor are 
probably underestimated, as is also illustrated by the fact 
that two individuals did not yet show a response on the 
fatigue and vigor scale after a cumulative dose of 0.94 mg 
LOR. 
To summarize the results: 
1. Heart rate during rest was reduced dose-dependently 
with an EDs0 of 0.13 mg LOR. 
2. LOR induced an increase in SRT (ED50>0.32) and 
fatigue (ED5o>0.47) and a decrease in vigor 
(ED5o>0.24). The EDso of subjective fatigue was 
significantly higher than the EDso of heart rate during 
rest. 
3. The CWT induced consistent increases in heart rate 
and plasma adrenaline levels, but LOR had no effect 
on the heart rate, MBP or catecholamine r sponse 
magnitudes to the CWT. 
4. LOR had no effect on state anxiety, or on MBP or 
plasma catecholamines, although a gradual increase in 
MBP and plasma noradrenaline was observed uring 
the rest periods of the PLA session. 
Discussion 
The aim of the present study was to separate sedative re- 
sponses to lorazepam from anxiolytic responses which 
are supposed to occur at lower doses than sedative re- 
sponses and to link either of these responses to effects on 
sympathetic adrenal-medullary activity. 
Our results show a clear sedative ffect of lorazepam 
as expressed by increased reaction time, increased num- 
ber of errors on the CWT, increased fatigue and de- 
creased vigor. Performance impairment, reduced atten- 
tion or sedation have been described after an oral dose 
of 2 mg LOR (Patat et at. 1987; Preston et at. 1989). In 
our study most of these responses occurred with an EDs0 
of 0.24 mg intravenously or higher, which is probably 
equivalent to an oral dose of approximately 0.5 mg or 
higher. 
Anxiolytic responses, however, were not observed as 
no effect of LOR on state anxiety or on any of the 
responses to the CWT could be detected, irrespective of 
the fact that the CWT reproducibly induced an increase 
in heart rate and plasma adrenaline levels. One might 
argue that the CWT as a stress-inducing performance 
task did not induce a relevant increase in anxiety in these 
healthy (non-anxious) volunteers and that therefore an 
anxiolytic effect of LOR could not be demonstrated. This 
is in line with the findings of File and Lister (t985), who 
report a failure of LOR to reduce experimentally- 
induced anxiety after oral doses of 1 and 2.5 mg. 
Since no subjective anxiety, or any effects of LOR on 
responses to the CWT were observed, the heart rate and 
adrenaline responses to each CWT may reflect an in- 
crease in effort mechanisms (Sanders 1983), which are 
necessary for the subject to cope with the task, rather 
than stress- or anxiety-related responses. Compensatory 
mechanisms as a result of subjective sedation may have 
partly masked a suppressing effect of LOR on the re- 
sponse magnitudes to the CWT, since motivation to 
perform a task is not negatively influenced by doses of 
LOR which induce sedation (File and Lister 1982). In 
order to establish whether the heart rate or adrenaline 
responses to the CWT are part of effort mechanisms 
necessary to perform a task, compensation mechanisms 
to overcome sedation, or stress-response mechanisms on 
which LOR has no influence, application of anxiolytics 
without sedative properties (such as buspirone; Cohn 
and Wilcox 1986) or anxiolytics with a specific influence 
on plasma catecholamines (such as alprazolam; Grant et 
al. t984) should be studied in a placebo-controlled de- 
sign. 
Evidence of direct or indirect involvement of the cen- 
tral benzodiazepine pathways in the regulation of sym- 
pathetic nervous system activity is scarce. Some studies 
report normal or increased heart rate after oral ad- 
ministration of 1-2.5 mg LOR (Elliott et al. 1970; File 
and Lister 1985), but other studies have shown a sup- 
pression of plasma catecholamine l vels and blood pres- 
sure by benzodiazepines at doses which induce sedation 
(Duka et al. 1986; Roy-Birne et al. 1988, 1989). Our data 
are in agreement with these last observations ince a 
cumulative dose of 0.94 mg LOR, which significantly 
induced subjective sedation, also suppressed plasma 
noradrenaline and MBP levels during rest. However, we 
found that heart rate already was reduced at lower doses 
with an EDs0 of 0.13 mg intravenously. Since plasma 
catecholamines and blood pressure were unaffected at 
83 
these doses of  LOR,  this effect may reflect an increase in 
vagal  st imulat ion of  the heart, rather than a suppression 
of  sympathet ic  activity. This effect occurred at dosages 
expected to exert an anxiolyt ic effect and not  sedative 
effects. Whether  it is indeed related to vagal st imulat ion 
and clinical anxiolysis,  however,  could not  be establ ished 
in the present exper iment and awaits further studies. 
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